Citadel Advisors’s Palisade Bio PALI Stock Holding History

Citadel Advisors’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25K	Sell	14,272 -1,687,139	-99%	-$3.07M	﹤0.01%	12624
2025 Q4	$4M	Buy	+1,701,411	New	+$3.27M	﹤0.01%	4655
2022 Q4	–	Sell	-38	Closed	-$3K	–	15292
2022 Q3	$3K	Buy	+38	New	+$8.04K	﹤0.01%	12407
2022 Q2	–	Sell	-93	Closed	-$74K	–	13774
2022 Q1	$74K	Buy	+93	New	+$75.2K	﹤0.01%	12536
2021 Q4	–	Sell	-14	Closed	-$28K	–	14479
2021 Q3	$28K	Hold	14	–	–	﹤0.01%	13588
2021 Q2	$42K	Buy	14 +8	+133%	+$36.3K	﹤0.01%	13400
2021 Q1	$48K	Buy	+6	New	+$40.5K	﹤0.01%	12919
2019 Q3	–	Sell	-1	Closed	-$18K	–	9602
2019 Q2	$18K	Hold	1	–	–	﹤0.01%	8960
2019 Q1	$31K	Hold	1	–	–	﹤0.01%	8986
2018 Q4	$20K	Buy	+1	New	+$57.4K	﹤0.01%	8756
2018 Q3	–	Hold	0	–	–	–	9067
2018 Q2	–	Hold	0	–	-$31K	–	9146
2018 Q1	–	Hold	0	–	–	–	8044
2017 Q4	–	Hold	0	–	–	–	8302
2017 Q3	–	Hold	0	–	–	–	7394
2016 Q3	–	Hold	0	–	-$3K	–	7609
2016 Q2	–	Hold	0	–	–	–	6756
2016 Q1	–	Hold	0	–	–	–	6290
2015 Q2	–	Hold	0	–	–	–	8973
2015 Q1	–	Hold	0	–	–	–	4975
2014 Q4	–	Hold	0	–	–	–	6938
2014 Q3	–	Hold	0	–	–	–	6087
2014 Q2	–	Hold	0	–	–	–	7521
2014 Q1	–	Hold	0	–	–	–	7597

Other funds holding PALI

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Citadel Advisors's PALI Position: Q1 2026 in Review

Citadel Advisors reduced its Palisade Bio (PALI) stake by 99% in Q1 2026, selling an estimated $3.07M and leaving 14,272 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #12624.

Citadel Advisors first reported a position in PALI in Q4 2018 and has held it in 10 quarters since. The position peaked at $4M in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

Citadel Advisors held 14,272 shares of Palisade Bio worth $25K as of Q1 2026.
Citadel Advisors sold 1,687,139 Palisade Bio shares in Q1 2026, an estimated $3.07M.
Palisade Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12624 holding.
Citadel Advisors first reported a position in Palisade Bio in Q4 2018 and has held it in 10 quarters since.
Citadel Advisors's Palisade Bio position peaked at $4M in Q4 2025.
96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.